Feature | February 19, 2014

Experimental Wireless Messaging Technology Remotely Monitors Patient Heart Conditions

LAPTOP-HF Telecardiology Remote Patient Monitoring ICM EP Lab Heart Failure ECG

February 19, 2014 — A new treatment option for heart disease is being tested at The University of Kansas Hospital that could be significant in telemedicine. Using an implantable monitoring device, the patient can hold a smartphone-type device to the chest and the device will relay info wirelessly from the heart implant to the doctors at the hospital. It allows doctors the ability to better personalize treatment for heart failure patients while giving those patients more control of their chronic condition.

The clinical trial is called LAPTOP-HF (Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy.) Dhanunjaya Lakkireddy, an electrophysiologist at The University of Kansas Hospital, said the LAPTOP-HF monitor can give heart patients and their doctors critical information immediately. 

"Before this device, any of these measurements had to be taken here in our office. Now with this technology, we can obtain the information from the patient's home," Lakkireddy said. "It's especially helpful for patients who live a long way from us. We can constantly monitor their condition and give them medication changes any time, rather than waiting for a scheduled appointment."

That's a huge benefit for Larry Stewart, who lives nearly two hours south of the hospital in Bronson, Kan. Before enrolling in the trial, Stewart and his wife had to make the journey to see Lakkireddy about every six weeks for congestive heart failure and atrial fibrillation.

Now, after having the device (which looks like a pacemaker) surgically implanted in his chest, all Stewart has to do each day is hold the small monitor (the size of a smartphone) up to his chest and the readings are electronically sent back to the doctor's office for instant analysis. 

"It makes me feel better that there's something there that's measuring and keeping an eye on my heart," Stewart said. 

It also means only making the trip to the doctor's office every three months, while still being monitored regularly, which is especially helpful during winter months when road conditions can be dangerous. 

St. Jude Medical developed the monitor. The University of Kansas Hospital is among the 75 sites in the United States chosen to evaluate the safety and effectiveness of the device.

For more information: www.kumed.com

Related Content

Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
NIAID Scientists Illuminate Mechanism of Increased Cardiovascular Risks With HIV
News | Cardiac Diagnostics| September 14, 2017
September 14, 2017 — Scientists at the National Institutes of Health have expanded the understanding of how chronic i
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
Overlay Init